STAT+: New results show Cassava’s Alzheimer’s drug has placebo-like efficacy
Cassava Sciences had long claimed that its experimental treatment for Alzheimer’s disease was capable of improving the cognition of patients — a benefit no other Alzheimer’s drug has ever shown.
But mid-stage study results updated on Tuesday now show the cognitive status of patients worsening to the point where Cassava’s drug, called simufilam, doesn’t look any more effective than a placebo.
Continue to STAT+ to read the full story…
Information Courtesy By: Adam Feuerstein, #HealthcareNews #Healthcare | Feeds
Cassava Sciences had long claimed that its experimental treatment for Alzheimer’s disease was capable of improving the cognition of patients — a benefit no other Alzheimer’s drug has ever shown.
But mid-stage study results updated on Tuesday now show the cognitive status of patients worsening to the point where Cassava’s drug, called simufilam, doesn’t look any more effective than a placebo.
Continue to STAT+ to read the full story…
Click For More Details
2023-01-25 02:08
Except for the headline, this story has not been edited by Healthcare Central is published from a syndicated feed.